ABOUT US

At Diaceutics we believe that every patient should have access to the right treatment at the right time to positively impact their disease outcome, and we are committed to solving commercialization challenges.

We provide the world's leading pharma and biotech companies with an end-to-end commercialization solution for the launch of precision medicine through our platform

DXRX - The Diagnostic Network®

Copyright © 2024, Diaceutics. All rights reserved

ACCELERATED

SMARTER

HCP ENGAGEMENT

THERAPY UPTAKE

Philadelphia

REACH THE RIGHT PHYSICIANS. ACT AT THE RIGHT TIME  

Using multimodal data and expert insights, we identify eligible patients within 48 hours, show which physicians are treating them, and engage those physicians with speed and precision, so you can build early traction, accelerate prescribing, and gain market share with speed and confidence.

274

tests ordered by reacting physicians 

28%

of physicians ordered a new test at least once during the 26 week period

33%

of physicians were successfully engaged during engagement campaign 

81

new therapy-eligible patients identified

When education is timely, trusted and targeted, physicians act faster, and more patients get the therapy they need


Let’s talk at Fierce Pharma Week

 Reach and Engage HCPs with Real-Time Clinical Diagnostic Data

Traditional pharma targeting misses as much as 60% of treating physicians and engages the remaining 40% months too late. Claims-based targeting only captures those who billed for treatment - not who tested, diagnosed, continues to monitor, or made the critical therapy decisions that drive patient outcomes.

 
Diaceutics real-time deterministic clinical data connects the patient’s health journey directly to HCP treatment decisions, today. This  is why Real World audience segments from Diaceutics enable brand marketers to engage targeted treaters earlier and faster, with curated messaging based on what’s actually happening real-time, not what happened months ago.

Discover the Diaceutics Difference

Unlock the power of precision in patient conversion. Diaceutics enables brands to engage HCPs at exactly the right moment - based on real-time clinical journeys, not outdated claims data.

Preview the audiences available today and meet us at Fierce Pharma Week to build a custom diagnostic journey tailored to your media plan.

 

Discover how Diaceutics helps physicians move from uncertainty to confident prescribing

Introducing Diaceutics Audiences:

Build prescriber confidence that drives action

See how real-time diagnostic data identifies eligible patients within 48 hours, enabling targeted, timely HCP engagement. 

Bridge the gap between insight and action, so no eligible patient is left behind.

Ready to drive smarter HCP engagement?

We partner with top 20 pharma and emerging biotech to accelerate therapy uptake whether you’re launching, scaling, or reigniting momentum. 

Supporting cross-functional teams in commercial, marketing, medical, data, access, and more, we deliver the insight and precision needed to move faster and reach every eligible patient. 

From oncology and rare disease to neurology, autoimmune, and beyond - we help you unlock uptake with smarter strategy, real-time physician action, and measurable impact.

Let’s build stronger adoption - together

September 8-11

Meet our team 

PATRICK MULLANEY

VP – ENGAGEMENT SOLUTIONS


REAL WORLD DATA AUDIENCE
PARTNERSHIPS LEAD

SENIOR CLIENT DIRECTOR

SENIOR CLIENT DIRECTOR

EMMA ARMSTRONG

NICHOLAS FREEBURN

GOSIA LEITCH

Meet Diaceutics at Fierce Pharma Week 2025

8 –September 11 | Pennsylvania Convention Center, Philadelphia

Our real-time data and in-house precision medicine expertise were used to guide digital engagement strategies to identify and target relevant physicians, as presented in our ASCO 2024 poster:

When every moment counts, speed matters. Physician Engage empowers you to reach the right prescribers with the right message fast so you can influence decisions before opportunities are lost.


Source: Effect of real-time data-driven physician engagement on appropriate precision oncology testing.